If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-04. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
=== Adaptive immune responses === Plain RNAs may be poor immunogens, but antibodies can easily be created against RNA-protein complexes. These types of antibodies are seen in many autoimmune diseases. There have not yet been reports of antibodies against siRNA bound to proteins. Some methods for siRNA delivery attach polyethylene glycol (PEG) to the oligonucleotide, reducing excretion and improving circulating half-life. However, a large Phase III trial of PEGylated RNA aptamer against factor IX had to be discontinued by Regado Biosciences because of a severe anaphylactic reaction to the PEG part of the RNA. This reaction led to death in some cases and raises significant concerns about siRNA delivery when PEGylated oligonucleotides are involved.
== Alternative medicine == With the growth of direct-to-consumer genetic testing, the alternative medicine industry has aggressively targeted a range of dubious tests and highly profitable quack treatments for claimed MTHFR polymorphisms, despite the lack of any demonstrated health effects of these mutations. The promotion of supplements and other treatments for MTHFR polymorphisms, especially centered on autistic spectrum disorder, have been characterised as "snake oil". Tests for MTHFR, while gaining popularity, are generally unnecessary because the association of MTHFR gene mutations with various diseases have not been established as clear-cut cause-and-effect relationship.
=== September === 1 September – Labour MP Jas Athwal sacks the letting agent managing his properties after a BBC investigation found they were infested with mould and ants. John Swinney gives his keynote speech to the SNP Annual Conference, saying that he will put the "people's priorities" at the heard of the Scottish Government, and that he will work to convince voters that Scottish independence is the "route" to delivering a fairer and stronger country. 2024 Social Democratic and Labour Party leadership election: Claire Hanna, the MP for Belfast South and Mid Down, confirms her intention to run as SDLP leader. 2 September – 2024 Conservative Party leadership election: Kemi Badenoch launches her leadership campaign with a speech in central London during which she says the Conservatives need to "stop acting like Labour". Former Labour Party leader Jeremy Corbyn unites with four other independent MPs to create the Independent Alliance, a pro-Gaza group and the joint fifth largest group in Parliament. 3 September – The Medicines (Gonadotrophin-Releasing Hormone Analogues) (Emergency Prohibition) (England, Wales and Scotland) Order 2024 ceases to have effect. A leaked letter penned by Cabinet Secretary Simon Case describes the previous Conservative government's failure to hold a spending review in its final years in office as a contributing factor towards uncertainty over the state of public finances. Case also disputes the Conservative stance that Labour's allegation that they have inherited an economic "black hole" is bringing the civil service into disrepute.
The IAEA conservatively classifies plutonium of all isotopic vectors as "direct-use" material, that is, "nuclear material that can be used for the manufacture of nuclear explosives components without transmutation or further enrichment".
Sources: en.wikipedia.org
Administration: Administers the Secretariat as well as looks after personal matters of the Chairman/Members and other Officers/Staff of the commission. All India Services: Recruitment to All India Services is done either by direct recruitment, through Civil Services Examination or by promotion from the State Service. The AIS Branch handles the promotions of State Service officers to the IAS, IPS and IFS. It also handles policy matters relating to All India Services and amendments in the 'Promotion Regulations' of respective services. Appointments: It carries out appointments to central services based on Promotion (based on proposals from various Ministries/Departments/Union Territories and from certain local bodies) and by the means of Deputation and Absorption. Examinations: It carries out merit-based selection and recommendation of candidates through various examinations such as the Engineering Services Examination, Combined Medical Services Examination, Defence Services Examination, Civil Services Examination, etc., to Group A and Group B Services of the Government of India. General: Primarily deals with day-to-day housekeeping work for the Commission, such as arrangements and facilitation for the conduct of Examinations by the UPSC, printing the Annual Report, etc.
==== Zonal necrosis ==== This is the most common type of drug-induced liver cell necrosis where the injury is largely confined to a particular zone of the liver lobule. It may manifest as a very high level of ALT and severe disturbance of liver function leading to acute liver failure.
== Catalytic mechanism == Lysine carboxypeptidase is produced exclusively in the liver and then is secreted into the blood shortly after. It functions best in an environment with neutral pH. The enzyme functions to break off arginine or lysine from the C-terminal of a polypeptide chain. Lysine is hydrolyzed more readily because it has a quicker turnover rate than arginine. The penultimate amino acid also contributes to the ease at which the reaction proceeds. Alanine and methionine result in the most efficient reactions while glycine significantly reduces reaction speed. Lysine carboxypeptidase utilizes metal ion catalysis in order to complete its reaction and has zinc (or another divalent cation like cobalt) as a necessary cofactor. Because of this, its actions can be inhibited by chelating factors which would remove the zinc from the enzyme complex. Zinc is bound to the active site of the enzyme and acts as a stabilizer. The positive charge of the zinc allows it to interact with the partial negative charge of the oxygen in a water molecule and form a bond. A nearby base will remove one of the hydrogens off of the oxygen molecule to stabilize it. Now, it can effectively act as a nucleophile; it will attack the carbonyl group of the protein to form a temporary tetrahedral. After some energetically favorable electron reconfiguration occurs, the result will be the terminal amino acid being cleaved off from the remainder of the polypeptide chain.
=== Clinical utility === A use of ion chromatography can be seen in argentation chromatography. Usually, silver and compounds containing acetylenic and ethylenic bonds have very weak interactions. This phenomenon has been widely tested on olefin compounds. The ion complexes the olefins make with silver ions are weak and made based on the overlapping of pi, sigma, and d orbitals and available electrons therefore cause no real changes in the double bond. This behavior was manipulated to separate lipids, mainly fatty acids from mixtures in to fractions with differing number of double bonds using silver ions. The ion resins were impregnated with silver ions, which were then exposed to various acids (silicic acid) to elute fatty acids of different characteristics. Detection limits as low as 1 μM can be obtained for alkali metal ions. It may be used for measurement of HbA1c, porphyrin and with water purification. Ion Exchange Resins(IER) have been widely used especially in medicines due to its high capacity and the uncomplicated system of the separation process. One of the synthetic uses is to use Ion Exchange Resins for kidney dialysis. This method is used to separate the blood elements by using the cellulose membraned artificial kidney. Another clinical application of ion chromatography is in the rapid anion exchange chromatography technique used to separate creatine kinase (CK) isoenzymes from human serum and tissue sourced in autopsy material (mostly CK rich tissues were used such as cardiac muscle and brain).
Topical gels are a topical drug delivery dosage form commonly used in cosmetics and treatments for skin diseases because of their advantages over cream and ointment. They are formed from a mixture of gelator, solvent, active drug, and other excipients, and can be classified into organogels and hydrogels. Drug formulation and preparation methods depend on the properties of the gelators, solvents, drug and excipients used.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.